Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916966 | 0.79 | CYP11B1 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL1180028 | 0.77 | CYP19A1 (0.49) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL5571001 | 0.74 | CYP19A1 (0.48) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL5133449 | 0.74 | CYP19A1 (0.48) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL5048062 | 0.74 | CYP19A1 (0.48) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL1768150 | 0.73 | CYP19A1 (0.43) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL1180397 | 0.72 | CYP19A1 (0.42) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL12313924 | 0.72 | CYP19A1 (0.45) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL8236808 | 0.72 | CYP19A1 (0.45) | CYP19A1CYP11B1CYP11B2KCNH2 | |
| SCHEMBL12871217 | 0.72 | CYP19A1 (0.45) | CYP19A1CYP11B1CYP11B2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101415716-B | Condensed imidazole derivatives as aldosterone synthase inhibitors | SPEEDEL EXPERIMENTA AG | 2012-12-12 | — | — | CN | disclosed |
| US-8076327-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076327-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076327-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-13 | — | — | US | disclosed |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799780-B2 | Condensed imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| EP-2004657-B1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| CN-101415716-A | Condensed imidazole derivatives as aldosterone synthase inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2009-04-22 | — | — | CN | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012068-A1 | Condensed Imidazole Derivatives as Aldosterone Synthase Inhibitors | CYP11B1, CYP11B2, REN | CYP19A1 51/4885CYP11B1 1/4885CYP11B2 2/4885 |
| US-20100305110-A1 | CONDENSED IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP11B2, REN | CYP19A1 50/4885CYP11B1 1/4885CYP11B2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.